omecamtiv mecarbil   Click here for help

GtoPdb Ligand ID: 8740

Synonyms: AMG 423 | AMG-423 | CK-1827452
PDB Ligand
Compound class: Synthetic organic
Comment: Omecamtiv mecarbil is an investigational small molecule which is a direct activator of cardiac myosin [3]. This compound is being investigated as a novel therapy for patients with chronic heart failure due to systolic dysfunction. Results from the first-in-man study are reported by Teerlink et al. (2011) [4].
Omecamtiv mecarbil is claimed in patent US7507735 B2 [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 86.8
Molecular weight 401.19
XLogP 1.06
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)N1CCN(CC1)Cc1cccc(c1F)NC(=O)Nc1ccc(nc1)C
Isomeric SMILES COC(=O)N1CCN(CC1)Cc1cccc(c1F)NC(=O)Nc1ccc(nc1)C
InChI InChI=1S/C20H24FN5O3/c1-14-6-7-16(12-22-14)23-19(27)24-17-5-3-4-15(18(17)21)13-25-8-10-26(11-9-25)20(28)29-2/h3-7,12H,8-11,13H2,1-2H3,(H2,23,24,27)
InChI Key RFUBTTPMWSKEIW-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Omecamtiv mecarbil is being evaluated in clinical trials as a therapy for heart failure [1,6].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Direct activation of cardiac myosin improves cardiac contractility without changing the calcium transient, as occurs with current inotropic therapies used improve cardiac function in congestive heart failure. The myosin present in the heart is a type II myosin and is a major component of sarcomeres, the basic units of cardiac muscle contraction. The MYH6 and MYH7 genes encode myosin heavy chain proteins which are expressed in the heart.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02929329 Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction Phase 3 Interventional Amgen Galactic-HF trial: Despite being better than placebo in preventing hospitalisations and other interventions in patients with heart failure with reduced ejection fraction (HFrEF), omecamtiv mecarbil did not extend patients' lives. 5